| Description | Helenalin is a selective inhibitor of transcription factor NF-κB by direct targeting of p65. It is an anti-inflammatory sesquiterpene lactone compound with alkylating activity. Through its ability to target the cysteine sulfhydryl groups in the p65 subunit of NF-κB, helenalin effectively inhibits its DNA binding. |
| In vitro | After 80 minutes, Helenalin (10 μM; 20-120 minutes) induces complete inhibition of NF-κB DNA binding [1]. Helenalin, the anti-inflammatory and anti-carcinogenic phytochemicals, is an effective inhibitor of periodic Skp2 accumulation which is an F-box protein mediating SCF E3 ligase ubiquitylation and degradation of both CKIs during S phase progression[3]. |
| In vivo | To immature male ICR mice, Helenalin (25 mg/kg; i.p.; 6 to 12 hours) administers, induced a rapid reduction in hepatic glutathione levels[2]. |
| molecular weight | 262.3 |
| Molecular formula | C15H18O4 |
| CAS | 6754-13-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Merrill JC, et al. Role of glutathione in the toxicity of the sesquiterpene lactones hymenoxon and helenalin. J Toxicol Environ Health. 1988;23(2):159-69. 2. Lyss G, et al. The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-kappaB by directly targeting p65. J Biol Chem. 1998 Dec 11;273(50):33508-16. 3. Fernandes KM, et al. Helenalin-mediated post-transcriptional regulation of p21(Cip1) inhibits 3T3-L1 preadipocyteproliferation. J Cell Biochem. 2008 Oct 15;105(3):913-21. |